Back to Browse Journals » Vascular Health and Risk Management » Volume 11

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

Authors Scherer DJ, Nicholls SJ

Received 9 October 2014

Accepted for publication 6 November 2014

Published 25 March 2015 Volume 2015:11 Pages 203—209

DOI https://doi.org/10.2147/VHRM.S40134

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Daniel Duprez

Daniel J Scherer,1 Stephen J Nicholls2

1Cardiovascular Investigation Unit, Royal Adelaide Hospital, 2South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia

Abstract: Despite the clinical benefits of lowering levels of low-density lipoprotein cholesterol, many patients continue to experience cardiovascular events. This residual risk suggests that additional risk factors require aggressive modification to result in more effective prevention of cardiovascular disease. Hypertriglyceridemia has presented a considerable challenge with regard to understanding its role in the promotion of cardiovascular risk. Increasing evidence has established a clear causal role for elevated triglyceride levels in vascular risk. As a result, there is increasing interest in the development of specific therapeutic strategies that directly target hypertriglyceridemia. This has seen a resurgence in the use of omega-3 fatty acids for the therapeutic lowering of triglyceride levels. The role of these agents and other emerging strategies to reduce triglyceride levels in order to decrease vascular risk are reviewed.

Keywords: hypertriglyceridemia, omega-3 fatty acid, fish oil, cardiovascular risk, lipids

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Lipidomics in vascular health: current perspectives

Kolovou G, Kolovou V, Mavrogeni S

Vascular Health and Risk Management 2015, 11:333-342

Published Date: 12 June 2015

Experimental study of sutureless vascular anastomosis with use of glued prosthesis in rabbits

Vokrri L, Qavdarbasha A, Rudari H, Ahmetaj H, Manxhuka-Kërliu S, Hyseni N, Porcu P, Cinquin P, Sessa C

Vascular Health and Risk Management 2015, 11:211-217

Published Date: 27 March 2015

Virtual reality simulation for the optimization of endovascular procedures: current perspectives

Rudarakanchana N, Van Herzeele I, Desender L, Cheshire NJW

Vascular Health and Risk Management 2015, 11:195-202

Published Date: 10 March 2015

Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms

Vacek TP, Rehman S, Neamtu D, Yu S, Givimani S, Tyagi SC

Vascular Health and Risk Management 2015, 11:173-183

Published Date: 27 February 2015

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus

Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA

Vascular Health and Risk Management 2015, 11:35-48

Published Date: 6 January 2015

How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study

Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S

Vascular Health and Risk Management 2014, 10:341-352

Published Date: 13 June 2014

Rivaroxaban in atrial fibrillation

Giorgi MA, Miguel LS

Vascular Health and Risk Management 2012, 8:525-531

Published Date: 30 August 2012